Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
9 p, 453.9 KB Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials / Strober, Bruce (Probity Medical Research) ; Gottlieb, Alice B (New York Medical College at Metropolitan Hospital) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot. Assistance Publique-Hôpitaux de Paris. Service de Dermatologie. Hôpital Saint-Louis) ; Chouela, E. (Universidad de Buenos Aires) ; Imafuku, S. (Department of Dermatology. Faculty of Medicine. Fukuoka University) ; Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Tan, H. (Pfizer Inc.) ; Valdez, H. (Pfizer Inc.) ; Gupta, P. (Pfizer Inc.) ; Kaur, M. (Pfizer Inc.) ; Frajzyngier, V. (Pfizer Inc.) ; Wolk, R. (Pfizer Inc.) ; Universitat Autònoma de Barcelona
Background: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. [...]
2019 - 10.1111/bjd.17149
British journal of dermatology, Vol. 180 Núm. 1 (january 2019) , p. 67-75  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.